Literature DB >> 23317145

Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.

Joe H Chang1, Morikatsu Wada, Nigel J Anderson, Daryl Lim Joon, Sze Ting Lee, Sylvia J Gong, Dishan H Gunawardana, John Sachinidis, Graeme O'Keefe, Hui K Gan, Vincent Khoo, Andrew M Scott.   

Abstract

BACKGROUND: This study investigates the use of (18)F-fluoromisonidazole (FMISO) PET-guided radiotherapy dose painting for potentially overcoming the radioresistant effects of hypoxia in head and neck squamous cell carcinoma (HNSCC).
MATERIAL AND METHODS: The study cohort consisted of eight patients with HNSCC who were planned for definitive radiotherapy. Hypoxic subvolumes were automatically generated on pre-radiotherapy FMISO PET scans. Three radiotherapy plans were generated for each patient: a standard (STD) radiotherapy plan to a dose of 70 Gy, a uniform dose escalation (UDE) plan to the standard target volumes to a dose of 84 Gy, and a hypoxia dose-painted (HDP) plan with dose escalation only to the hypoxic subvolume to 84 Gy. Plans were compared based on tumor control probability (TCP), normal tissue complication probability (NTCP), and uncomplicated tumor control probability (UTCP).
RESULTS: The mean TCP increased from 73% with STD plans to 95% with the use of UDE plans (p < 0.001) and to 93% with HDP plans (p < 0.001). The mean parotid NTCP increased from 26% to 44% with the use of UDE plans (p = 0.003), and the mean mandible NTCP increased from 2% to 27% with the use of UDE plans (p = 0.001). There were no statistically significant differences between any of the NTCPs between the STD plans and HDP plans. The mean UTCP increased from 48% with STD plans to 66% with HDP plans (p = 0.016) and dropped to 37% with UDE plans (p = 0.138).
CONCLUSION: Hypoxia-targeted radiotherapy dose painting for head and neck cancer using FMISO PET is technically feasible, increases the TCP without increasing the NTCP, and increases the UTCP. This approach is superior to uniform dose escalation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23317145     DOI: 10.3109/0284186X.2012.759273

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  25 in total

1.  Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.

Authors:  Abdallah S R Mohamed; Carlos E Cardenas; Adam S Garden; Musaddiq J Awan; Crosby D Rock; Sarah A Westergaard; G Brandon Gunn; Abdelaziz M Belal; Ahmed G El-Gowily; Stephen Y Lai; David I Rosenthal; Clifton D Fuller; Michalis Aristophanous
Journal:  Radiother Oncol       Date:  2017-07-31       Impact factor: 6.280

Review 2.  Computerized PET/CT image analysis in the evaluation of tumour response to therapy.

Authors:  W Lu; J Wang; H H Zhang
Journal:  Br J Radiol       Date:  2015-02-27       Impact factor: 3.039

3.  Imaging Hypoxia with ¹⁸F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis.

Authors:  Mark Muzi; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

4.  Dosimetry study of 18F-FMISO + PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer.

Authors:  H Li; D Xu; X Han; Q Ruan; X Zhang; Y Mi; M Dong; S Guo; Y Lin; B Wang; G Li
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

Review 5.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

Review 6.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

Review 7.  Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.

Authors:  Sonja Stieb; Afroditi Eleftheriou; Geoffrey Warnock; Matthias Guckenberger; Oliver Riesterer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-20       Impact factor: 9.236

Review 8.  F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.

Authors:  Joseph G Rajendran; Kenneth A Krohn
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

9.  Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications?

Authors:  Yao Ding; Abdallah S R Mohamed; Jinzhong Yang; Rivka R Colen; Steven J Frank; Jihong Wang; Eslam Y Wassal; Wenjie Wang; Michael E Kantor; Peter A Balter; David I Rosenthal; Stephen Y Lai; John D Hazle; Clifton D Fuller
Journal:  Pract Radiat Oncol       Date:  2014-12-17

10.  The tumor core boost study: A feasibility study of radical dose escalation to the central part of large tumors with an integrated boost in the palliative treatment setting.

Authors:  Olaf Wittenstein; Fabian Krause; Mirko Fischer; Justus Domschikowski; Mirko Nitsche; Christoph Henkenberens; Daniel Habermehl; Juergen Dunst
Journal:  Strahlenther Onkol       Date:  2022-07-20       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.